David Peden

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9348673/publications.pdf

Version: 2024-02-01

47409 73587 6,712 112 49 79 citations h-index g-index papers 114 114 114 8229 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Development and Application of an Open Tool for Sharing and Analyzing Integrated Clinical and Environmental Exposures Data: Asthma Use Case. JMIR Formative Research, 2022, 6, e32357.	0.7	3
2	Gamma-tocopherol, a major form of vitamin E in diets: Insights into antioxidant and anti-inflammatory effects, mechanisms, and roles in disease management. Free Radical Biology and Medicine, 2022, 178, 347-359.	1.3	45
3	JACI: Global is now ready for boarding!. , 2022, 1, 1.		O
4	EAACI position paper on the clinical use of the bronchial allergen challenge: Unmet needs and research priorities. Allergy: European Journal of Allergy and Clinical Immunology, 2022, 77, 1667-1684.	2.7	12
5	The clear and persistent impact of air pollution on chronic respiratory diseases: a call for interventions. European Respiratory Journal, 2021, 57, 2002981.	3.1	21
6	Acute and durable effect of inhaled hypertonic saline on mucociliary clearance in adult asthma. ERJ Open Research, 2021, 7, 00062-2021.	1.1	5
7	Prenatal exposure to particulate matter air pollution: AÂpreventable risk for childhood asthma. Journal of Allergy and Clinical Immunology, 2021, 148, 716-718.	1.5	6
8	COVID-19, asthma, and biological therapies: What we need to know. World Allergy Organization Journal, 2020, 13, 100126.	1.6	90
9	Acute asthma management during SARS-CoV2-pandemic 2020. World Allergy Organization Journal, 2020, 13, 100125.	1.6	35
10	International expert consensus on the management of allergic rhinitis (AR) aggravated by air pollutants. World Allergy Organization Journal, 2020, 13, 100106.	1.6	94
11	Can the effects of outdoor air pollution on asthma be mitigated?. Journal of Allergy and Clinical Immunology, 2019, 143, 2016-2018.e1.	1.5	16
12	Inferring Respiratory Minute Volume from Wrist Motion. , 2019, 2019, 6935-6938.		3
13	Emerging concepts and challenges in implementing the exposome paradigm in allergic diseases and asthma: a Practall document. Allergy: European Journal of Allergy and Clinical Immunology, 2019, 74, 449-463.	2.7	77
14	Environmental Control: The First Tenet of Allergy. Journal of Allergy and Clinical Immunology: in Practice, 2018, 6, 36-37.	2.0	1
15	Assessing the impact of air pollution on childhood asthma morbidity: how, when, and what to do. Current Opinion in Allergy and Clinical Immunology, 2018, 18, 124-131.	1.1	40
16	Safety and benefits of inhaled hypertonic saline following airway challenges with endotoxin and allergen in asthmatics. Journal of Asthma, 2017, 54, 957-960.	0.9	11
17	Environmental determinants of allergy and asthma in early life. Journal of Allergy and Clinical Immunology, 2017, 140, 1-12.	1.5	218
18	Occupational Asthma. Journal of Allergy and Clinical Immunology: in Practice, 2016, 4, 783-784.	2.0	0

#	Article	IF	CITATIONS
19	Low-Power Wearable Systems for Continuous Monitoring of Environment and Health for Chronic Respiratory Disease. IEEE Journal of Biomedical and Health Informatics, 2016, 20, 1251-1264.	3.9	159
20	Clinically focused exome sequencing identifies an homozygous mutation that confers <scp>DOCK</scp> 8 deficiency. Pediatric Allergy and Immunology, 2016, 27, 96-98.	1.1	4
21	IL-1 receptor antagonist reduces endotoxin-induced airway inflammation in healthy volunteers. Journal of Allergy and Clinical Immunology, 2015, 135, 379-385.	1.5	79
22	Allergenicity of roasted peanuts treated with a non-human digestive protease. Food Research International, 2015, 69, 341-347.	2.9	17
23	The Relationship of Mucus Concentration (Hydration) to Mucus Osmotic Pressure and Transport in Chronic Bronchitis. American Journal of Respiratory and Critical Care Medicine, 2015, 192, 182-190.	2.5	136
24	Wearable wireless sensors for chronic respiratory disease monitoring. , 2015, , .		22
25	Inflammatory Response of Monocytes to Ambient Particles Varies by Highway Proximity. American Journal of Respiratory Cell and Molecular Biology, 2014, 51, 802-809.	1.4	29
26	Environmental effects on immune responses in patients with atopy and asthma. Journal of Allergy and Clinical Immunology, 2014, 134, 1001-1008.	1.5	93
27	Vitamin E, \hat{I}^3 -tocopherol, reduces airway neutrophil recruitment after inhaled endotoxin challenge in rats and in healthy volunteers. Free Radical Biology and Medicine, 2013, 60, 56-62.	1.3	61
28	Severe DRESS Syndrome Managed With Therapeutic Plasma Exchange. Pediatrics, 2013, 131, e945-e949.	1.0	27
29	Inflammatory Cytokine Response to Ambient Particles Varies due to Field Collection Procedures. American Journal of Respiratory Cell and Molecular Biology, 2013, 48, 497-502.	1.4	5
30	Bronchoscopy-Derived Correlates of Lung Injury following Inhalational Injuries: A Prospective Observational Study. PLoS ONE, 2013, 8, e64250.	1.1	30
31	Vitamin E forms inhibit IL-13/STAT6-induced eotaxin-3 secretion by up-regulation of PAR4, an endogenous inhibitor of atypical PKC in human lung epithelial cells. Journal of Nutritional Biochemistry, 2012, 23, 602-608.	1.9	27
32	Role of GSTM1 in resistance to lung inflammation. Free Radical Biology and Medicine, 2012, 53, 721-729.	1.3	40
33	Asthma outcomes: Exacerbations. Journal of Allergy and Clinical Immunology, 2012, 129, S34-S48.	1.5	248
34	Modulation of asthma by endotoxin. Clinical and Experimental Allergy, 2011, 41, 9-19.	1.4	58
35	Effect of inhaled dust mite allergen on regional particle deposition and mucociliary clearance in allergic asthmatics. Clinical and Experimental Allergy, 2011, 41, 1719-1728.	1.4	29
36	The role of oxidative stress and innate immunity in O ₃ and endotoxinâ€induced human allergic airway disease. Immunological Reviews, 2011, 242, 91-105.	2.8	50

#	Article	lF	CITATIONS
37	GSTM1 modulation of IL-8 expression in human bronchial epithelial cells exposed to ozone. Free Radical Biology and Medicine, 2011, 51, 522-529.	1.3	34
38	Lung Function and Inflammatory Responses in Healthy Young Adults Exposed to 0.06 ppm Ozone for 6.6 Hours. American Journal of Respiratory and Critical Care Medicine, 2011, 183, 1215-1221.	2.5	174
39	Flow cytometry of sputum: assessing inflammation and immune response elements in the bronchial airways. Inhalation Toxicology, 2011, 23, 392-406.	0.8	55
40	Enhancement of systemic and sputum granulocyte response to inhaled endotoxin in people with the GSTM1 null genotype. Occupational and Environmental Medicine, 2011, 68, 783-785.	1.3	28
41	Phosphorylation of p65 Is Required for Zinc Oxide Nanoparticle–Induced Interleukin 8 Expression in Human Bronchial Epithelial Cells. Environmental Health Perspectives, 2010, 118, 982-987.	2.8	77
42	Protective Role of Interleukin-10 in Ozone-Induced Pulmonary Inflammation. Environmental Health Perspectives, 2010, 118, 1721-1727.	2.8	38
43	Environmental and occupational allergies. Journal of Allergy and Clinical Immunology, 2010, 125, S150-S160.	1.5	150
44	Comparative airway inflammatory response of normal volunteers to ozone and lipopolysaccharide challenge. Inhalation Toxicology, 2010, 22, 648-656.	0.8	56
45	Low-level ozone exposure induces airways inflammation and modifies cell surface phenotypes in healthy humans. Inhalation Toxicology, 2010, 22, 593-600.	0.8	56
46	\hat{I}^3 -Tocopherol Attenuates Ozone-induced Exacerbation of Allergic Rhinosinusitis in Rats. Toxicologic Pathology, 2009, 37, 481-491.	0.9	34
47	In vivo uptake of inhaled particles by airway phagocytes is enhanced in patients with mild asthma compared with normal volunteers. Thorax, 2009, 64, 313-320.	2.7	37
48	Combination Treatment with High-Dose Vitamin C and Alpha-Tocopherol does not Enhance Respiratory-Tract Lining Fluid Vitamin C Levels in Asthmatics. Inhalation Toxicology, 2009, 21, 173-181.	0.8	28
49	\hat{l}^3 -Tocopherol prevents airway eosinophilia and mucous cell hyperplasia in experimentally induced allergic rhinitis and asthma. Clinical and Experimental Allergy, 2008, 38, 501-511.	1.4	73
50	In vivo \hat{I}^3 -tocopherol supplementation decreases systemic oxidative stress and cytokine responses of human monocytes in normal and asthmatic subjects. Free Radical Biology and Medicine, 2008, 45, 40-49.	1.3	76
51	Advances in environmental and occupational respiratory disease in 2007. Journal of Allergy and Clinical Immunology, 2008, 121, 1359-1362.	1.5	5
52	Climate change and allergic disease. Journal of Allergy and Clinical Immunology, 2008, 122, 443-453.	1.5	246
53	Sublingual-oral administration of standardized allergenic extracts: phase 1 safety and dosing results. Annals of Allergy, Asthma and Immunology, 2008, 100, 475-481.	0.5	45
54	SUBLINGUAL-ORAL ADMINISTRATION OF STANDARDIZED ALLERGENIC EXTRACTS: PHASE 1 SAFETY AND DOSING RESULTS. Annals of Allergy, Asthma and Immunology, 2008, 101, 445-446.	0.5	0

#	Article	IF	CITATIONS
55	Endotoxin Augments Myeloid Dendritic Cell Influx into the Airways in Patients with Allergic Asthma. American Journal of Respiratory and Critical Care Medicine, 2008, 177, 1307-1313.	2.5	48
56	Fluticasone Propionate Protects against Ozone-Induced Airway Inflammation and Modified Immune Cell Activation Markers in Healthy Volunteers. Environmental Health Perspectives, 2008, 116, 799-805.	2.8	52
57	Circulating neutrophil CD14 expression and the inverse association of ambient particulate matter on lung function in asthmatic children. Annals of Allergy, Asthma and Immunology, 2007, 99, 244-253.	0.5	21
58	Ozone enhances markers of innate immunity and antigen presentation on airway monocytes in healthy individuals. Journal of Allergy and Clinical Immunology, 2007, 120, 719-722.	1.5	49
59	Coarse Particulate Matter (PM 2.5–10) Affects Heart Rate Variability, Blood Lipids, and Circulating Eosinophils in Adults with Asthma. Environmental Health Perspectives, 2007, 115, 709-714.	2.8	137
60	Ozone enhancement of lower airway allergic inflammation is prevented by \hat{I}^3 -tocopherol. Free Radical Biology and Medicine, 2007, 43, 1176-1188.	1.3	55
61	Biological material on inhaled coarse fraction particulate matter activates airway phagocytes in vivo in healthy volunteers. Journal of Allergy and Clinical Immunology, 2006, 117, 1396-1403.	1.5	161
62	Attenuation of host defense function of lung phagocytes in young cystic fibrosis patients. Journal of Cystic Fibrosis, 2006, 5, 17-25.	0.3	64
63	Recurrent syncope and anaphylaxis as presentation of systemic mastocytosis in a pediatric patient: Case report and literature review. Journal of the American Academy of Dermatology, 2006, 54, S210-S213.	0.6	26
64	How Exposures to Biologics Influence the Induction and Incidence of Asthma. Environmental Health Perspectives, 2006, 114, 620-626.	2.8	51
65	Nasal Responses in Asthmatic and Nonasthmatic Subjects Following Exposure to Diesel Exhaust Particles. Inhalation Toxicology, 2006, 18, 589-594.	0.8	24
66	The Influence of Variation in Type and Pattern of Symptoms on Assessment in Pediatric Asthma. Pediatrics, 2006, 118, 619-625.	1.0	48
67	Allergens and Pollutants. , 2006, , 247-287.		0
68	Incidence of allergy and allergy symptoms among workers exposed to laboratory animals. Occupational and Environmental Medicine, 2005, 62, 766-771.	1.3	56
69	Gene-Environment Interactions in Asthma and Other Respiratory Diseases. Annual Review of Medicine, 2005, 56, 383-400.	5.0	104
70	Acute LPS inhalation in healthy volunteers induces dendritic cell maturation in vivo. Journal of Allergy and Clinical Immunology, 2005, 115, 345-350.	1.5	62
71	The epidemiology and genetics of asthma risk associated with air pollution. Journal of Allergy and Clinical Immunology, 2005, 115, 213-219.	1.5	128
72	Progression of self-reported symptoms in laboratory animal allergy. Journal of Allergy and Clinical Immunology, 2005, 116, 127-132.	1.5	44

#	Article	lF	Citations
73	Health effects of air pollution. Journal of Allergy and Clinical Immunology, 2004, 114, 1116-1123.	1.5	669
74	Inhalation of low-dose endotoxin favors local TH2 response and primes airway phagocytes in vivo. Journal of Allergy and Clinical Immunology, 2004, 114, 1325-1331.	1.5	55
75	Efficacy and Safety of Fluticasone Propionate/Salmeterol HFA 134A MDI in Patients with Mildâ€toâ€Moderate Persistent Asthma. Journal of Asthma, 2004, 41, 797-806.	0.9	45
76	Circulating CD11b expression correlates with the neutrophil response and airway mCD14 expression is enhanced following ozone exposure in humans. Clinical Immunology, 2004, 111, 126-131.	1.4	35
77	Effect of Ozone Exposure on Airway Responses to Inhaled Allergen in Asthmatic Subjects. Chest, 2004, 125, 2328-2335.	0.4	49
78	Does air pollution cause asthma exacerbations in children?. Annals of Allergy, Asthma and Immunology, 2003, 90, 1-2.	0.5	1
79	Effect of inhaled endotoxin on airway and circulating inflammatory cell phagocytosis and CD11b expression in atopic asthmatic subjects. Journal of Allergy and Clinical Immunology, 2003, 112, 353-361.	1.5	58
80	Low-dose airborne endotoxin exposure enhances bronchial responsiveness to inhaled allergen in atopic asthmatics. Journal of Allergy and Clinical Immunology, 2003, 112, 1241-1243.	1.5	55
81	Health consequences associated with frequent wheezing in adolescents without asthma diagnosis. European Respiratory Journal, 2003, 22, 781-786.	3.1	35
82	CD14-dependent airway neutrophil response to inhaled LPS: Role of atopy. Journal of Allergy and Clinical Immunology, 2001, 107, 31-35.	1.5	93
83	Blunting airway eosinophilic inflammation results in a decreased airway neutrophil response to inhaled LPS in patients with atopic asthma: A role for CD14. Journal of Allergy and Clinical Immunology, 2001, 108, 577-580.	1.5	40
84	Air pollution in asthma: effect of pollutants on airway inflammation. Annals of Allergy, Asthma and Immunology, 2001, 87, 12-17.	0.5	95
85	Allergen provocation augments endotoxin-induced nasal inflammation in subjects with atopic asthma. Journal of Allergy and Clinical Immunology, 2000, 105, 475-481.	1.5	101
86	Increased specific airway reactivity of persons with mild allergic asthma after 7.6 hours of exposure to 0.16 ppm ozoneâ † â † â † â † â * 1204.	1.5	99
87	Eosinophil influx to the nasal airway after local, low-level LPS challenge in humans⯆⯆⯆. Journal of Allergy and Clinical Immunology, 1999, 104, 388-394.	1.5	63
88	Inhaled fluticasone propionate delivered by means of two different multidose powder inhalers is effective and safe in a large pediatric population with persistent asthma. Journal of Allergy and Clinical Immunology, 1998, 102, 32-38.	1.5	85
89	Prolonged acute exposure to 0.16 ppm ozone induces eosinophilic airway inflammation in asthmatic subjects with allergies. Journal of Allergy and Clinical Immunology, 1997, 100, 802-808.	1.5	89
90	Allergen bronchoprovocation of patients with mild allergic asthma after ozone exposureâ [*] †, â [*] †â [*] †, â [*] , â [*] â [*] of Allergy and Clinical Immunology, 1996, 98, 563-572.	Journal 1.5	49

#	Article	IF	CITATIONS
91	Nasal lavage cytokines in normal, allergic, and asthmatic school-age children American Journal of Respiratory and Critical Care Medicine, 1995, 152, 1290-1296.	2.5	78
92	Ozone exposure has both a priming effect on allergen-induced responses and an intrinsic inflammatory action in the nasal airways of perennially allergic asthmatics American Journal of Respiratory and Critical Care Medicine, 1995, 151, 1336-1345.	2.5	193
93	Nasal Secretion of the Ozone Scavenger Uric Acid. The American Review of Respiratory Disease, 1993, 148, 455-461.	2.9	61
94	Airway hyperresponsiveness in patients with microvascular angina. Evidence for a diffuse disorder of smooth muscle responsiveness Circulation, 1990, 82, 2011-2017.	1.6	35
95	Uric acid is a major antioxidant in human nasal airway secretions Proceedings of the National Academy of Sciences of the United States of America, 1990, 87, 7638-7642.	3.3	158
96	Bradykinin and Respiratory Mucous Membranes: Analysis of Bradykinin Binding Site Distribution and Secretory Responses <i>In Vitro</i> and <i>In Vivo</i> . The American Review of Respiratory Disease, 1990, 141, 706-714.	2.9	96
97	Gastrin-releasing peptide in human nasal mucosa Journal of Clinical Investigation, 1990, 85, 998-1005.	3.9	50
98	Approaches to the Measurement of Chemiluminescence or Bioluminescence in a Single Cell. , 1989 , , $407-415$.		0
99	Diminished chemiluminescent responses of polymorphonuclear leukocytes in severely and moderately preterm neonates. Journal of Pediatrics, 1987, 111, 904-906.	0.9	27
100	Studies of neonatal polymorphonuclear leukocyte function using a novel microanalytic chemiluminescence technique. Microchemical Journal, 1986, 34, 222-229.	2.3	3
101	Studies of luminol-dependent whole-blood chemiluminescence induced by platelet-activating factor (PAF). Microchemical Journal, 1985, 31, 261-271.	2.3	2
102	The measurement of chemiluminescence, aggregation, and 5-hydroxy-6,8,11,14-eicosatetraenoic acid production of n-formyl-methioninyl-leucyl-phenylalanine-stimulated human polymorphonuclear leukocytes. Microchemical Journal, 1985, 31, 22-28.	2.3	2
103	Impairment of leukocyte myeloperoxidase bactericidal mechanisms with ketamine (Ketalar $\hat{A}^{@}$). Agents and Actions, 1983, 13, 59-62.	0.7	8
104	A novel method for measuring initial-burst chemiluminescence in a liquid scintillation counter using the myeloperoxidase-H20î—,Clâ^' reaction. Microchemical Journal, 1982, 27, 221-230.	2.3	4
105	Comparison of the effects of antioxidant non-steroidal anti-inflammatory drugs against myeloperoxidase and hypochlorous acid luminol-enhanced chemiluminescence. Agents and Actions, 1982, 12, 232-238.	0.7	38
106	Antioxidation theory of non-steroidal anti-inflammatory drugs based upon the inhibition of luminol-enhanced chemiluminescence from the myeloperoxidase reaction. Agents and Actions, 1982, 12, 371-376.	0.7	50
107	Multipurpose radiomatic automated flow liquid scintillation counter system for measurement of burst or delayed chemiluminescence reactions: Model-drug inhibition with luminol-dependent myeloperoxidase. Microchemical Journal, 1982, 27, 276-289.	2.3	2
108	Inhibition by nonsteroidal antiinflammatory drugs of luminol-dependent human-granulocyte chemiluminescence and [3H]FMLP binding. Inflammation, 1982, 6, 113-125.	1.7	27

#	Article	IF	CITATIONS
109	Abnormal responses of granulocytes in chronic granulomatous disease. Biochimica Et Biophysica Acta - Biomembranes, 1981, 645, 49-53.	1.4	19
110	PRELIMINARY EVENTS LEADING TO THE PRODUCTION OF LUMINOL-DEPENDENT CHEMILUMINESCENCE BY HUMAN GRANULOCYTES., 1981,, 45-53.		3
111	ARACHIDONATE - BASED CHEMILUMINESCENCE IN HUMAN GRANULOCYTES AND PLATELETS USING THE MONOLIGHT 301 (DRUG STUDIES). , 1981, , 385-390.		1
112	Luminol-dependent chemiluminescence analysis of human platelets. Microchemical Journal, 1980, 25, 514-523.	2.3	6